Invivyd advances measles antibody program. The biopharmaceutical company discussed progress in its REVOLUTION clinical program and development of a novel measles monoclonal antibody candidate designed for treatment and prevention of measles. The company presented updates during an earnings call with research analysts from major investment firms. Leadership including the Chief Scientific Officer and Chief Medical Officer outlined the advancement of their potential first-and-best-in-class therapeutic approach. This development represents significant progress in Invivyd's pipeline as the company continues to advance its infectious disease treatment portfolio. Investors are monitoring the clinical progress closely as measles prevention therapeutics represent an important market opportunity.
Post from MarketNews_en
Log in to interact with content.